strategic partnership

An open book with pages turning on a wooden table set

Erasca looks to partner off late-stage melanoma asset

The asset, which Erasca picked up from Novartis for $20 million, would be the first targeted therapy in NRASm melanoma if it were to make it to market.

Gabrielle Masson May 13, 2025 10:38am

Catamaran Bio sends out life raft in tough financing climate

Jan 30, 2024 2:42pm

patients medicine doctor clinical trial practice physician

Velocity teams with Privia Health for clinical research sites

Jul 12, 2023 11:50am

Medsir teams with Oncoclínicas in Latin America

Mar 31, 2022 3:35pm

Philips adds AI, 3D mapping to mobile X-ray platform

Jan 18, 2022 11:32am

Bristol Myers inks $3B in Century, ArsenalBio cell therapy deals

Jan 10, 2022 10:31am